HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsOmar Khan, Nicholas B. La Thangue|Immunology and Cell Biology|2011Cited by 443
Atypical E2F activity restrains APC/C <sup>CCS52A2</sup> function obligatory for endocycle onsetTim Lammens, Lieven De Veylder, Leila Kheibarshekan et al.|Proceedings of the National Academy of Sciences|2008Cited by 183
Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour responseWojciech Barczak, Nicholas B. La Thangue|Nature Communications|2023Cited by 115
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent MechanismMaria I. New, Nicholas B. La Thangue|Cancer Research|2016Cited by 44
The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunityGeng Liu, Nicholas B. La Thangue|Communications Biology|2023Cited by 16